PYXS Oct 2024 5.000 put
| Previous close | 2.4500 |
| Open | 2.4500 |
| Bid | 0.7500 |
| Ask | 3.9000 |
| Strike | 5.00 |
| Expiry date | 2024-10-18 |
| Day's range | 2.4500 - 2.4500 |
| Contract range | N/A |
| Volume | |
| Open interest | 35 |
GlobeNewswirePyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger
BOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Michael A. Metzger to its Board of Directors, effective June 10, 2024. Mr. Metzger has over 25 years of experience in the biopharmaceutical sector, currently serving as Chief Executive Officer and as a member of the Board of Directors of Syndax Pharmaceuticals, Inc. (Na
- GlobeNewswire
Pyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in a fireside chat on Thursday, June 6, 2024 at 9:00 AM Eastern Time at the Jefferies Global Healthcare Conference in New York City, where members of management will also host investor one-on-one meetings. A
GlobeNewswirePyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024
PYX-201 Phase 1 trial clinical readout on track for fall of 2024 Executive Leadership Team expanded with the appointment of Stephen Worsley as Senior Vice President, Chief Business Officer PYX-106 Phase 1 trial clinical readout on track for 2H 2024 Expected cash runway into 2H 2026 BOSTON, May 14, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today reported financial
